Muscle and Nerve
Displaying 1 - 13 of 13
Folkvaljon, F., Gertz, M., Gillmore, J. D., Khella, S., Masri, A., Maurer, M. S., Cruz, M. W., Wixner, J., Chen, J., Reicher, B., Kwoh, J., Yarlas, A., & Berk, J. L. (2024). Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health‐Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis. Muscle & Nerve, 71(1), 96–107. Portico. https://doi.org/10.1002/mus.28299
Publication Date
Columbia Affiliation
Berry, J. D., Paganoni, S., Harms, M. B., Shneider, N., Andrews, J., Miller, T. M., Babu, S., Sherman, A. V., Harris, B. T., Provenzano, F. A., Phatnani, H. P., Shefner, J., Garret, M. A., Ladha, S. S., Tsou, A. Y., Mohan, P., Igne, C., & Bowser, R. (2024). Access for ALL in ALS: A large‐scale, inclusive, collaborative consortium to unlock the molecular and genetic mechanisms of amyotrophic lateral sclerosis. Muscle & Nerve, 70(6), 1140–1150. Portico. https://doi.org/10.1002/mus.28244
Publication Date
Columbia Affiliation
View
Karam, C., Mauermann, M. L., Gonzalez‐Duarte, A., Kaku, M. C., Ajroud‐Driss, S., Brannagan, T. H., & Polydefkis, M. (2024). Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts. Muscle & Nerve, 69(3), 273–287. Portico. https://doi.org/10.1002/mus.28026
Publication Date
Columbia Affiliation
Tavee, J., Brannagan, T. H., Lenihan, M. W., Muppidi, S., Kellermeyer, L., & D Donofrio, P. (2023). Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee. Muscle & Nerve, 68(4), 356–374. Portico. https://doi.org/10.1002/mus.27922
Publication Date
Columbia Affiliation
Crawford, T. O., Swoboda, K. J., De Vivo, D. C., Bertini, E., Hwu, W., Finkel, R. S., Kirschner, J., Kuntz, N. L., Nazario, A. N., Parsons, J. A., Pechmann, A., Ryan, M. M., Butterfield, R. J., Topaloglu, H., Ben‐Omran, T., Sansone, V. A., Jong, Y., Shu, F., … Zhu, C. (2023). Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of theNURTUREstudy. Muscle & Nerve, 68(2), 157–170. Portico. https://doi.org/10.1002/mus.27853
Publication Date
Columbia Affiliation
Cheng, R., Feng, J., Goodwin, A. M., Uher, D., Rao, A. K., McDermott, M. P., De Vivo, D. C., Ewing Garber, C., & Montes, J. (2022). Perceived exertion is not a substitute for fatiguability in spinal muscular atrophy. Muscle & Nerve, 68(1), 81–84. Portico. https://doi.org/10.1002/mus.27765
Publication Date
Columbia Affiliation
Lee, I., Stingone, J. A., Chan, R. B., & Mitsumoto, H. (2023). Utilizing machine learning and lipidomics to distinguish primary lateral sclerosis from amyotrophic lateral sclerosis. Muscle & Nerve, 67(4), 306–310. Portico. https://doi.org/10.1002/mus.27797
Publication Date
Columbia Affiliation
Sadjadi, R., Kelly, K., Glanzman, A. M., Montes, J., Linsenmayer, M., Tellez, M., Bartlett, A., Heintzman, S., Kolb, S. J., Arnold, W. D., & El‐Sheikh, B. (2023). Psychometric evaluation of modified spinal muscular atrophy functional rating scale (SMAFRS) in adult patients using Rasch analysis. Muscle & Nerve, 67(3), 239–243. Portico. https://doi.org/10.1002/mus.27785
Publication Date
Columbia Affiliation
Cook, M., Pasnoor, M., Ajroud‐Driss, S., Brannagan, T. H., Dimachkie, M. M., & Allen, J. A. (2022). CIDP prognosis in patients with IVIG treatment‐related fluctuations. Muscle & Nerve, 67(1), 69–73. Portico. https://doi.org/10.1002/mus.27746
Publication Date
Columbia Affiliation
De León, A. M., Aban, I., McPherson, T., Granit, V., Benatar, M., Cutter, G., & Lee, I. (2022). Impact of the COVID‐19 pandemic on patients with myasthenia gravis: A survey of the Myasthenia Gravis Foundation of America MG patient registry. Muscle & Nerve, 67(1), 25–32. Portico. https://doi.org/10.1002/mus.27743
Publication Date
Columbia Affiliation
Thakore, N. J., Lapin, B. R., Mitsumoto, H., & Pooled Resource Open‐Access ALS Clinical Trials Consortium. (2022). Early initiation of riluzole may improve absolute survival in amyotrophic lateral sclerosis. Muscle & Nerve, 66(6), 702–708. Portico. https://doi.org/10.1002/mus.27724
Publication Date
Columbia Affiliation
Darras, B. T., Guye, S., Hoffart, J., Schneider, S., Gravestock, I., Gorni, K., Fuerst‐Recktenwald, S., Scalco, R. S., Finkel, R. S., & De Vivo, D. C. (2022). Distribution of weight, stature, and growth status in children and adolescents with spinal muscular atrophy: An observational retrospective study in the United States. Muscle & Nerve, 66(1), 84–90. Portico. https://doi.org/10.1002/mus.27556
Publication Date
Columbia Affiliation
Miller, R. G., Zhang, R., Bracci, P. M., Azhir, A., Barohn, R., Bedlack, R., Benatar, M., Berry, J. D., Cudkowicz, M., Kasarskis, E. J., Mitsumoto, H., Manousakis, G., Walk, D., Oskarsson, B., Shefner, J., & McGrath, M. S. (2022). Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre‐specified and post hoc analyses. Muscle & Nerve, 66(1), 39–49. Portico. https://doi.org/10.1002/mus.27511
Publication Date
Columbia Affiliation